A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)

NCT ID: NCT02229877

Last Updated: 2022-07-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-06
• Study Completion Date: 2015-05-22

Brief Summary

The purpose of this study is to: determine the effect of stomach pH on the multiple dose pharmacokinetics (PK) of gefapixant (AF-219); assess the effect of multiple doses of gefapixant on various sensory assessments; and, assess the safety and tolerability of gefapixant.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Gefapixant + Omeprazole

Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days

+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days

Group Type: EXPERIMENTAL

Omeprazole

Intervention Type: DRUG

40 mg oral capsules administered twice daily for 8.5 days

Gefapixant

Intervention Type: DRUG

Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days

Gefapixant

Intervention Type: DRUG

Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days

Gefapixant

Intervention Type: DRUG

Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days

Interventions

Omeprazole

40 mg oral capsules administered twice daily for 8.5 days

Intervention Type: DRUG

Gefapixant

Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days

Intervention Type: DRUG

Gefapixant

Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days

Intervention Type: DRUG

Gefapixant

Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days

Intervention Type: DRUG

Other Intervention Names

Prilosec; AF-219; MK-7264; AF-219; MK-7264; AF-219; MK-7264

Eligibility Criteria

Inclusion Criteria

Must be informed of the nature of the study and have provided written informed voluntary consent;

Able to speak, read, and understand English;

Healthy males or females, of any race, between 18 and 55 years of age, inclusive;

Body mass index (BMI) >18.5 and <32.0 kg/m2 and weigh 50 - 100 kg;

In good general health ;

Non-smokers for at least 5 years;

If a female of child-bearing potential (i.e., have not undergone a hysterectomy or bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of child-bearing potential agree to use 2 forms of acceptable birth control;

Exclusion Criteria

Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease;

Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication;

Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay fever during the time of the year that dosing will be taking place;

History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton pump inhibitors within 12 months of Screening;

Have a positive screening test for Helicobacter pylori;

QTcB >450 msec in males or >460 msec in females;

Known or suspected hypersensitivity or allergic reaction to any of the components of gefapixant or omeprazole capsules;

If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose;

Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of the first dose of study drug;

Chronic use of any systemic medications; use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications including antacids, high dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug;

Past or current history or evidence of drug or alcohol abuse, use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre dose;

Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration;

Positive urine cotinine test at Screening or Day 1 pre dose;

Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody;

Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication;

Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Celerion

INDUSTRY

Sponsor Role: collaborator

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Terry O'Reilly, M.D.

Role: PRINCIPAL_INVESTIGATOR

Celerion

References

Gupta P, Hussain A, Ford AP, Smith S, Nussbaum JC, Stoch A, Iwamoto M. Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. Clin Pharmacol Drug Dev. 2022 Sep;11(9):1054-1067. doi: 10.1002/cpdd.1105. Epub 2022 May 5.

Reference Type: RESULT

PMID: 35510785 (View on PubMed)

Other Identifiers

AF219-011

Identifier Type: OTHER

Identifier Source: secondary_id

7264-011

Identifier Type: -

Identifier Source: org_study_id